TACT-Safety
The Effect of Tranexamic Acid on Oncologic Outcomes: The TACT-SAFETY study – Retrospective study Nature et objective :We hypothesize that TXA during cancer surgery is safe and does not increase the risk of cancer recurrence. To address this hypothesis, we aim to extend the follow up of TACT patients beyond the peri-operative period to assess the […]
Pilot project exercise (UQAM)
Optimizing exercise prescription for prostate cancer patients: a pilot study based on participant preferences Nature et objective :A challenge for health professionals is to find adjuvant therapies with a low level of toxicity to combine with standard treatments in order to alleviate the burden of treatment in patients with prostate cancer. Physical activity (PA) is interesting, […]
V940-005
Phase 2, Randomized, Double-blind, Placebo- and Active-comparator controlled Clinical Study of Adjuvant V940 (mRNA-4157) Plus Pembrolizumab Versus Adjuvant Placebo Plus Pembrolizumab in Participants With High-risk Muscle-invasive Urothelial Carcinoma Post-radical Resection Nature and objective :The purpose of this study is to assess the safety and efficacy of V940 in combination with pembrolizumab (MK-3475) compared to pembrolizumab alone […]
CAAA617B12203 (PSMACare)
An International Prospective Open-label, Multi-center, Randomized, non-comparative Phase II Study of Lutetium [177Lu] vipivotide tetraxetan (AAA617) alone and Lutetium [177Lu] vipivotide tetraxetan (AAA617) in combination with Androgen Receptor Pathway Inhibitors in patients with PSMA PET scan positive Castration-Resistant Prostate Cancer Nature and objective :The purpose of this study is to evaluate the efficacy and safety of […]
CAAA617A12402 (Phase 4)
A Phase IV, Post-Authorization Safety Study to Investigate the Long-Term Safety of Lutetium (177Lu) Vipivotide Tetraxetan in Adult Participants With Prostate Cancer Nature and objective :The purpose of this post-marketing study is to further characterize the long-term outcome of known or potential risks for lutetium (177Lu) vipivotide tetraxetan also known as [177Lu]Lu-PSMA-617. The study also […]
PAnTHA
A Phase 1 open-label, first-in-human, multi-center study to evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of 225Ac-PSMA-Trillium in participants with advanced metastatic castration-resistant prostate cancer (mCRPC) Nature and objective :The PAnTHA study aims to assess the safety, tolerance, pharmacokinetics, and preliminary efficacy of 225Ac-PSMA-Trillium, a targeted alpha therapy that is a new class of […]
SUMMIT
Real-world clinical study evaluating the performance of the Optilume® BPH catheter system in men with symptomatic benign prostatic hyperplasia (SUMMIT) Nature et objective :Benign prostatic hypertrophy (BPH) is a benign enlargement of the prostate, common in older men and sometimes in younger men as young as 31 years old. Symptoms include urinary problems such as delayed […]
EvoPar
Double-blind, placebo-controlled, randomized, two-cohort phase III study to evaluate AZD5305 A Randomized, 2-cohort, Double-blind, Placebo-controlled, Phase III Study of AZD5305 in Combination with Physician’s Choice New Hormonal Agents in Patients with HRRm and non-HRRm Metastatic Castration-Sensitive Prostate Cancer (EvoPAR-Prostate01) Nature et objective :This is a research project to determine whether the study drug “AZD5305”, given in […]
MK-5684-003
Phase 3, Randomized, Open-Label Trial of MK-5684 Versus Abiraterone Acetate or Enzalutamide in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC) Previously Treated With a next-generation hormonal agent (NHA) and taxane-based chemotherapy. (MK-5684-003) Nature et objective:This trial is testing MK-5864 in men with metastatic castration-resistant prostate cancer (mCRPC). This trial will compare MK-5684 to abiraterone acetate […]
PROSTEP-002
Detection and monitoring of metastases using PET/CT imaging using the 18F-DCFPyL (PyL) tracer, in patients starting enzalutamide to treat castration-resistant prostate cancer with small number of metastases, an equivocal result or no metastases on conventional imaging (PROSTEP-002). Nature and objective :This is a study for patients with castration-resistant prostate cancer with a small number of metastases. […]
